CD8A and ovarian carcinoma: To further assess the inhibitory effect of iTregs on CD8+ T cell-mediated cytotoxicity against ovarian cancer cells, in vitro-activated CD8+ T cells were co-cultured in 96-well plates with varying ratios of iTregs (1:0, 1:1, and 2:1).